BioXcel Therapeutics, Inc.
BTAIQOTCCIK 1720893HealthcareFiscal year ends Dec 31
Reports and events: 227 filings
Newest first, by EDGAR acceptance time (Eastern). Each filing’s page lists its documents on sec.gov and, for 10-K and 10-Q reports, the extracted sections.
What the forms are: 10-K, 10-Q, 8-K, Form 4, DEF 14A, Schedule 13D, Schedule 13G, amendments, accession numbers.
| Filed | Form | What it is | Accession number |
|---|---|---|---|
| 2026-10-3017:15 ET | 8-K | 2.01 Completion of an acquisition or disposition; 5.02 Departure or appointment of officers or directors; 5.03 Amendment to articles or bylaws; 9.01 Financial statements and exhibits | 0001104659-26-120737 |
| 2026-09-0107:01 ET | 8-K | 2.03 New direct financial obligation; 3.01 Delisting notice | 0001104659-26-104106 |
| 2026-08-2806:00 ET | 8-K | 1.01 Entry into a material agreement; 1.03 Bankruptcy or receivership | 0001104659-26-102570 |
| 2026-08-2507:15 ET | 8-K | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001104659-26-100532 |
| 2026-08-2407:00 ET | 8-K | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001104659-26-099900 |
| 2026-08-1316:31 ET | 10-Q | Quarterly reportPeriod 2026-06-30 | 0001104659-26-095965 |
| 2026-08-1107:00 ET | 8-K | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001104659-26-093710 |
| 2026-08-0307:00 ET | 8-K | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001104659-26-089436 |
| 2026-07-0606:00 ET | 8-K | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001104659-26-080501 |
| 2026-05-1507:07 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001104659-26-061773 |
| 2026-05-1507:05 ET | 10-Q | Quarterly reportPeriod 2026-03-31 | 0001104659-26-061769 |
| 2026-04-1717:00 ET | 8-K | 3.02 Unregistered sale of equity; 9.01 Financial statements and exhibits | 0001104659-26-044952 |
| 2026-04-0106:58 ET | 8-K | 8.01 Other events | 0001104659-26-038174 |
| 2026-03-2717:02 ET | 10-K | Annual reportPeriod 2025-12-31 | 0001104659-26-036214 |
| 2026-03-2707:21 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001104659-26-035661 |
| 2026-03-1116:30 ET | 8-K | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001104659-26-026409 |
| 2026-02-1207:05 ET | 8-K | 8.01 Other events | 0001104659-26-013840 |
| 2026-02-0617:00 ET | 8-K | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001104659-26-011595 |
| 2026-01-2007:00 ET | 8-K | 8.01 Other events | 0001104659-26-004787 |
| 2026-01-1207:02 ET | 8-K | 8.01 Other events | 0001104659-26-002697 |
| 2025-12-1516:30 ET | 8-K | 5.07 Shareholder vote results | 0001104659-25-121180 |
| 2025-11-1217:00 ET | DEF 14A | Proxy statementPeriod 2025-12-12 | 0001104659-25-110491 |
| 2025-11-1209:01 ET | 10-Q | Quarterly reportPeriod 2025-09-30 | 0001104659-25-109880 |
| 2025-11-1207:11 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001104659-25-109732 |
| 2025-11-1008:00 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-25-108840 |
| 2025-10-3007:15 ET | 8-K | 8.01 Other events | 0001104659-25-104009 |
| 2025-10-1407:00 ET | 8-K | 8.01 Other events | 0001104659-25-098992 |
| 2025-09-1508:30 ET | 8-K | 7.01 Regulation FD disclosure; 8.01 Other events | 0001104659-25-089773 |
| 2025-09-1006:30 ET | 8-K | 8.01 Other events | 0001104659-25-088800 |
| 2025-08-2707:01 ET | 8-K | 8.01 Other events | 0001104659-25-083402 |
| 2025-08-1817:16 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-25-079880 |
| 2025-08-1807:05 ET | 8-K | 8.01 Other events | 0001104659-25-079459 |
| 2025-08-1509:18 ET | 8-K | 8.01 Other events | 0001104659-25-079042 |
| 2025-08-1209:02 ET | 10-Q | Quarterly reportPeriod 2025-06-30 | 0001558370-25-011158 |
| 2025-08-1208:05 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001104659-25-076501 |
| 2025-08-1117:00 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001104659-25-076214 |
| 2025-08-1107:30 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-25-075915 |
| 2025-08-0607:19 ET | 8-K | 8.01 Other events | 0001104659-25-074514 |
| 2025-08-0107:12 ET | 8-K | 8.01 Other events | 0001104659-25-072900 |
| 2025-07-2107:15 ET | 8-K | 8.01 Other events | 0001104659-25-069149 |
| 2025-07-1508:00 ET | 8-K | 8.01 Other events | 0001104659-25-067951 |
| 2025-05-2707:00 ET | 8-K | 8.01 Other events | 0001104659-25-052704 |
| 2025-05-1209:00 ET | 10-Q | Quarterly reportPeriod 2025-03-31 | 0001558370-25-007269 |
| 2025-05-1207:15 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001104659-25-047013 |
| 2025-04-0316:32 ET | 8-K | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001104659-25-031713 |
| 2025-03-2816:05 ET | 10-K | Annual reportPeriod 2024-12-31 | 0001558370-25-003985 |
| 2025-03-2716:15 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001104659-25-028776 |
| 2025-03-2117:00 ET | 8-K | 3.01 Delisting notice | 0001104659-25-026708 |
| 2025-03-2107:00 ET | 8-K | 8.01 Other events | 0001104659-25-026388 |
| 2025-03-0416:30 ET | 8-K | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001104659-25-020349 |
Source: SEC EDGAR, the company’s filing index. Last ingested by Listed: Oct 30, 2026, 17:24 ET. Listed shows no prices and gives no investment advice.